Anoro Elipta may be better than Bevespi Aerosphere or Stiolto Respimat at lowering risk of chronic obstructive pulmonary lung disease flares.

Umeclidinium-vilanterol is associated with improved clinical outcomes in symptomatic patients with chronic obstructive pulmonary disease.

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic obstructive ...

The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...

Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for about three months, a new study has revealed. This research by The University ...